64 results
424B5
TRML
Tourmaline Bio Inc
26 Jan 24
Prospectus supplement for primary offering
4:08pm
eye disease (“TED”) as our beachhead indication for our FcRn+ strategy. TED is an autoimmune disease characterized by autoantibody-mediated activation … for patients with immune, inflammatory and other diseases.
Our Strategy
We seek to identify and develop transformative medicines that have
424B5
TRML
Tourmaline Bio Inc
24 Jan 24
Prospectus supplement for primary offering
9:20pm
diseases, compared to FcRn inhibitors. We have identified thyroid eye disease (“TED”) as our beachhead indication for our FcRn+ strategy. TED … for assets that we believe have standard-of-care changing potential for patients with immune, inflammatory and other diseases.
Our Strategy
We seek
8-K
EX-99.2
d70nk xbaadu7qiuqtub
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
gftzx306i
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
3b7jb4nd
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
qqgsg f6r
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
425
amp34nzh
10 Oct 23
Business combination disclosure
4:32pm
8-K/A
wco4c
10 Oct 23
Other Events
4:30pm
425
fbi1tomb
6 Oct 23
Business combination disclosure
5:27pm
8-K
ahb7maif mltcm
6 Oct 23
Other Events
5:26pm
425
fcr67q779446 ata
26 Sep 23
Business combination disclosure
8:24am
8-K
lgqphh p2zub
26 Sep 23
Regulation FD Disclosure
8:21am
8-K
EX-99.1
55mq64xk
26 Sep 23
Regulation FD Disclosure
8:21am
424B3
lqpyyv
15 Sep 23
Prospectus supplement
6:31am
425
i73majbnr66r
13 Sep 23
Business combination disclosure
9:14am